Teva Pharmaceutical Industries (TEVA)
(Delayed Data from NYSE)
$12.88 USD
+0.02 (0.16%)
Updated Apr 22, 2024 04:00 PM ET
After-Market: $12.89 +0.01 (0.08%) 7:58 PM ET
3-Hold of 5 3
A Value A Growth C Momentum A VGM
Price, Consensus and EPS Surprise
TEVA 12.88 +0.02(0.16%)
Will TEVA be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for TEVA based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for TEVA
Zacks Industry Outlook Highlights Teva, Dr. Reddy's and Viatris
3 Generic Drug Stocks to Watch Amid Challenging Market Prospects
TEVA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Bausch (BHC) Soars 6.4%: Is Further Upside Left in the Stock?
Will Corcept (CORT) Bank on Korlym in 2024 Amid Stiff Rivalry?
GSK Follows Rivals, to Cap Out-of-Pocket Inhaler Cost in US
Other News for TEVA
US Supreme Court reportedly declines to hear Vanda patent case
Vanda Pharmaceuticals responds to U.S. Supreme Court denial of petition
Alvotech/Teva bring new partner to expand access for Humira biosimilar in U.S.
Unveiling Pfizer's Potent Cocktail: Key Drivers Of Free Cash Flow Growth
Alvotech, Teva signs deal to expand access for Humira biosimilar in U.S.